CUP diagnostics
CUP epidemiology
British Journal of Cancer
CUP guidelines
CUP treatments
Archive
- New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
- Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
- Characterisation and outcomes of patients referred to a regional cancer of unknown primary team
- Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
- Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
- Progress in refining the clinical management of cancer of unknown primary in the molecular era
Supportive care & Quality of life
Other
Archive
- Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia
- How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action
- Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
- Stakeholders’ expectations of precision medicine: A qualitative study to identify areas of (mis) alignment
- Systematic review of the CUP trials characteristics and perspectives for next-generation studies
- CUP Research Jos Friends
CUP JOURNEY
CUPFOUNDJO
CUPP-NL
CUPISCO TRIAL
ROCHE
NATURE COMMU.
Register here for updates
Missie Tumor Onbekend
Fannius Scholtenstraat 69,
1051EV, Amsterdam,
The Netherlands
Sarah Jennifer Knott Foundation,
38 Belgrave Road,
Rathmines,
D06 HW222,
Republic of Ireland
All Rights Reserved | Web Design by SNDE VISUAL Design & DIADEMADISARA
